人工多能性幹細胞（iPSC）の世界市場レポート 2025年

人工多能性幹細胞（iPSC）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.6％で52億9,000万米ドルに成長します。予測期間の成長は、慢性疾患の有病率の増加、ゲノムプロジェクトの成長、IPSC由来の疾患モデルの開発、遺伝性疾患の有病率の増加、政府の取り組み、技術の急速な向上などに起因すると考えられます。予測期間における主な動向としては、パーキンソン病（PD）用多能性幹細胞の開発、戦略的共同研究・提携、人工多能性幹細胞IPSC由来nk細胞の開発、細胞治療用人工多能性幹細胞（iPSC）の開発、再生医療研究開発への投資、IPSC拡大培地の開発、個別化IPSCの開発、I型糖尿病用多能性幹細胞の開発などが挙げられます。

人工多能性幹細胞市場は、主に慢性疾患の有病率の増加に牽引され、著しい成長を遂げています。心臓病、がん、脳卒中、糖尿病などの治療には、あらゆる組織源から得られ、胚性幹細胞を模倣するように遺伝子改変された人工多能性幹細胞が有効です。慢性疾患と闘うパートナーシップ（PFCD）の報告書によると、調査対象となった1億3300万人のアメリカ人の45％が、少なくとも一つの慢性疾患を抱えています。同報告書はまた、米国における死亡者10人のうち7人、約170万人が慢性疾患によるものであると推定しており、人工多能性幹細胞治療が潜在的な影響力を持つことを強調しています。慢性疾患の罹患率の増加は、人工多能性幹細胞治療市場の需要増加の主な要因です。

人工多能性幹細胞市場の成長に寄与しているのは、神経疾患の有病率の上昇です。神経系に影響を及ぼすこれらの疾患には、急性脊髄損傷、アルツハイマー病、筋萎縮性側索硬化症（ALS）などの疾患が含まれます。多能性幹細胞は、パーキンソン病やアルツハイマー病などの神経疾患に対して、疾患のメカニズムを研究し、薬物試験を行い、再生療法を進歩させるための貴重なプラットフォームを提供します。例えば、アルツハイマー病協会によると、2023年には65歳以上のアメリカ人のうち670万人がアルツハイマー病に罹患すると推定され、2050年には1270万人に達すると予測されています。このような神経疾患の増加傾向は、人工多能性幹細胞市場の重要な促進要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界人工多能性幹細胞（iPSC） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の人工多能性幹細胞（iPSC）市場：成長率分析
• 世界の人工多能性幹細胞（iPSC）市場の実績：規模と成長, 2019-2024
• 世界の人工多能性幹細胞（iPSC）市場の予測：規模と成長, 2024-2029, 2034F
• 世界人工多能性幹細胞（iPSC）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の人工多能性幹細胞（iPSC）市場派生細胞タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肝細胞
• 線維芽細胞
• ケラチノサイト
• 羊膜細胞
• その他の派生細胞
• 世界の人工多能性幹細胞（iPSC）市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 学術調査
• 医薬品の発見と毒性研究
• 再生医療
• 細胞および遺伝子治療
• 世界の人工多能性幹細胞（iPSC）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 調査室
• 世界の人工多能性幹細胞（iPSC）市場肝細胞のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物毒性試験のためのiPSC由来肝細胞
• 疾患モデルと再生療法
• 世界の人工多能性幹細胞（iPSC）市場線維芽細胞のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 創傷治癒と組織修復のためのiPSC由来皮膚細胞
• 線維芽細胞に基づく疾患調査
• 世界の人工多能性幹細胞（iPSC）市場、ケラチノサイトのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 皮膚科学調査のためのiPSC由来皮膚細胞
• 皮膚再生療法
• 世界の人工多能性幹細胞（iPSC）市場羊膜細胞のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 出生前調査のためのiPSC由来細胞
• 羊水ベースの再生医療への応用
• 世界の人工多能性幹細胞（iPSC）市場、その他の派生細胞タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 神経疾患モデルのためのニューロン
• 心臓病研究のための心筋細胞
• 血管調査のための内皮細胞

第7章 地域別・国別分析

• 世界の人工多能性幹細胞（iPSC）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の人工多能性幹細胞（iPSC）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 人工多能性幹細胞（iPSC）市場：競合情勢
• 人工多能性幹細胞（iPSC）市場：企業プロファイル
  • FUJIFILM Holdings Corporation（FUJIFILM Cellular Dynamics, Inc）Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific, Inc Overview, Products and Services, Strategy and Financial Analysis
  • Takara Bio, Inc Overview, Products and Services, Strategy and Financial Analysis
  • Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
  • Astellas Pharma Inc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• ViaCyte, Inc
• Ncardia
• REPROCELL USA, Inc
• Japan Tissue Engineering Co., Ltd
• Merck KGaA
• Cynata Therapeutics Limited
• Dainippon Sumitomo Pharma
• Shenzhen Bioscience
• Shanghai Cell Therapy Group
• Car-T Bio
• JW therapeutics
• Fosun Kite Biotechnology
• Shanghai UniCar Therapy
• Takaria Bio
• SEED Biosciences SA

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 人工多能性幹細胞（iPSC）市場2029：新たな機会を提供する国
• 人工多能性幹細胞（iPSC）市場2029：新たな機会を提供するセグメント
• 人工多能性幹細胞（iPSC）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Induced pluripotent stem cells are regenerated stem cells created from an existing adult cell, such as hepatocytes, fibroblasts, keratinocytes, or neurons. This process entails the introduction of specific genes that prompt the cell to become pluripotent, allowing it to differentiate into any cell type in the body, including heart, brain, and liver cells.

The principal derived cell types from induced pluripotent cells include hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. Hepatocytes, as the liver's primary functional cells, play a crucial role in an extensive range of metabolic, endocrine, and secretory functions. These cells find applications in various fields such as academic research, drug development and discovery, toxicity screening, and regenerative medicine, and are utilized in sectors including hospitals and research laboratories.

The induced pluripotent stem cell (iPSC) market research report is one of a series of new reports from The Business Research Company that provides induced pluripotent stem cell (iPSC) market statistics, including induced pluripotent stem cell (iPSC) industry global market size, regional shares, competitors with an induced pluripotent stem cell (iPSC) market share, detailed induced pluripotent stem cell (iPSC) market segments, market trends and opportunities, and any further data you may need to thrive in the induced pluripotent stem cell (iPSC) industry. This induced pluripotent stem cell (iPSC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The induced pluripotent stem cell (iPSC) market size has grown rapidly in recent years. It will grow from $3.3 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to increasing healthcare expenditure, a rise in funding, rising awareness of stem cell products' medicinal potential, use of induced pluripotent stem cell (IPSC) based drug discovery, increasing demand for personalized medicine and cost-effective benefits of IPSC for drug discovery.

The induced pluripotent stem cell (iPSC) market size is expected to see strong growth in the next few years. It will grow to $5.29 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to an increasing prevalence of chronic diseases, growth in genomic projects, development of IPSC-derived disease models, an increasing prevalence of genetic diseases, government initiatives and a rapid increase in technology. Major trends in the forecast period include development of pluripotent stem cells for Parkinson's disease (PD), strategic collaborations and partnerships, development of induced pluripotent stem cell IPSC-derived nk cells, development of induced pluripotent stem cell (IPSC) for cell therapy, investment in regenerative medicine research and development, development of IPSC expansion medium, development of personalized IPSC and development of pluripotent stem cells for type I diabetes.

The induced pluripotent stem cell market is witnessing significant growth, driven primarily by the increasing prevalence of chronic disorders. Conditions such as heart disease, cancer, stroke, and diabetes find treatment avenues in induced pluripotent stem cells, which are obtained from any tissue source and genetically modified to emulate embryonic stem cells. According to a report by the Partnership to Fight Chronic Disorder (PFCD), 45% of the 133 million Americans surveyed had at least one chronic disorder. The report also estimates that 7 out of 10 deaths in the USA, approximately 1.7 million, result from chronic disorders, emphasizing the potential impact of induced pluripotent stem cell treatment. The rising incidence of chronic diseases is a key driver for the increasing demand in the induced pluripotent stem cell treatment market.

Contributing to the growth of the induced pluripotent stem cell market is the escalating prevalence of neurological disorders. These disorders, affecting the nervous system, encompass conditions such as acute spinal cord injury, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS). Pluripotent stem cells offer a valuable platform for studying disease mechanisms, conducting drug testing, and advancing regenerative therapies for neurological conditions such as Parkinson's and Alzheimer's disease. For instance, according to the Alzheimer's Association, an estimated 6.7 million Americans aged 65 and older will have Alzheimer's in 2023, with projections reaching 12.7 million by 2050. This upward trend in neurological disorders is a significant driver for the induced pluripotent stem cell market.

Companies are actively seeking strategic partnerships and collaborations to expand their geographic reach and enhance product portfolios. Bristol Myers Squibb and Century Therapeutics, in January 2022, joined forces to develop iPSC-derived allogenic cell therapies targeting acute myeloid leukemia and multiple myeloma. Similarly, Evotec and Sernova announced a strategic partnership in May 2022 to develop iPSC-based beta cell replacement therapy for treating type 1 and type 2 diabetes.

Major companies in the induced pluripotent stem cell (iPSC) market are collaborating to advance iPSC technology, aiming to enhance applications in regenerative medicine, improve disease modeling, accelerate drug discovery, and develop personalized therapeutic solutions. Induced pluripotent stem cell (iPSC) technology encompasses the scientific processes and methodologies used to reprogram adult somatic cells, such as skin or blood cells, back into a pluripotent state, allowing them to differentiate into any cell type in the body. For example, in April 2024, SCG Cell Therapy Pte Ltd, a Singapore-based biotechnology firm, teamed up with the Agency for Science, Technology and Research, a statutory board in Singapore, to establish joint laboratories focused on advancing cellular immunotherapies. This initiative, supported by nearly S$30 million, highlights Singapore's dedication to promoting biotechnology and healthcare solutions. The collaboration aims to create scalable manufacturing processes for GMP-grade iPSC products, addressing the challenges of translating laboratory innovations into clinically viable therapies.

In May 2024, Theragent Inc., a US-based biotechnology company, formed a partnership with Pluristyx Inc. This collaboration aims to expand Theragent's portfolio by leveraging Pluristyx's expertise in providing induced pluripotent stem cell (iPSC) products. Pluristyx Inc. is a US-based biotechnology company that specializes in iPSC products.

Major companies operating in the induced pluripotent stem cell (iPSC) market include FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc, Takara Bio, Inc, Lonza Group AG, Astellas Pharma Inc, ViaCyte, Inc, Ncardia, REPROCELL USA, Inc, Japan Tissue Engineering Co., Ltd, Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, Takaria Bio, SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, MSD, Pfizer, Roche, Pharmasyntez, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, GlaxoSmithKline, Parexel, Bayer, Fate Therapeutics, Athersys, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, VistaGen Therapeutics, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, BioHeart

North America was the largest region in the induced pluripotent stem cell (IPSC) market in 2024. Western Europe was the second largest region in the global induced pluripotent stem cell (IPSC) market share. The regions covered in the induced pluripotent stem cell (IPSC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the induced pluripotent stem cell (IPSC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Induced Pluripotent Stem Cell (iPSC) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on induced pluripotent stem cell (ipsc) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for induced pluripotent stem cell (ipsc) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The induced pluripotent stem cell (ipsc) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cell Types
• 2) By Application: Academic Research, Drug Discovery And Toxicity Studies, Regenerative Medicine, Cell And Gene Therapy
• 3) By End-User: Hospitals, Research Laboratories
• Subsegments:
• 1) By Hepatocytes: iPSC-Derived Liver Cells For Drug Toxicity Testing; Disease Modeling And Regenerative Therapies
• 2) By Fibroblasts: iPSC-Derived Skin Cells For Wound Healing And Tissue Repair; Fibroblast-Based Disease Research
• 3) By Keratinocytes: iPSC-Derived Skin Cells For Dermatological Research; Skin Regeneration Therapies
• 4) By Amniotic Cells: iPSC-Derived Cells For Prenatal Research; Amniotic Fluid-Based Regenerative Applications
• 5) By Other Derived Cell Types: Neurons For Neurological Disease Modeling; Cardiomyocytes For Heart Disease Studies; Endothelial Cells For Vascular Research
• Companies Mentioned: FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc); Thermo Fisher Scientific, Inc; Takara Bio, Inc; Lonza Group AG; Astellas Pharma Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Induced Pluripotent Stem Cell (iPSC) Market Characteristics

3. Induced Pluripotent Stem Cell (iPSC) Market Trends And Strategies

4. Induced Pluripotent Stem Cell (iPSC) Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Induced Pluripotent Stem Cell (iPSC) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Induced Pluripotent Stem Cell (iPSC) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Induced Pluripotent Stem Cell (iPSC) Market Growth Rate Analysis
• 5.4. Global Induced Pluripotent Stem Cell (iPSC) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Induced Pluripotent Stem Cell (iPSC) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Induced Pluripotent Stem Cell (iPSC) Total Addressable Market (TAM)

6. Induced Pluripotent Stem Cell (iPSC) Market Segmentation

• 6.1. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatocytes
• Fibroblasts
• Keratinocytes
• Amniotic Cells
• Other Derived Cells
• 6.2. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Academic Research
• Drug Discovery And Toxicity Studies
• Regenerative Medicine
• Cell And Gene Therapy
• 6.3. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Research Laboratories
• 6.4. Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation Of Hepatocytes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• iPSC-Derived Liver Cells For Drug Toxicity Testing
• Disease Modeling And Regenerative Therapies
• 6.5. Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation Of Fibroblasts, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• iPSC-Derived Skin Cells For Wound Healing And Tissue Repair
• Fibroblast-Based Disease Research
• 6.6. Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation Of Keratinocytes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• iPSC-Derived Skin Cells For Dermatological Research
• Skin Regeneration Therapies
• 6.7. Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation Of Amniotic Cells, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• iPSC-Derived Cells For Prenatal Research
• Amniotic Fluid-Based Regenerative Applications
• 6.8. Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation Of Other Derived Cell Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neurons For Neurological Disease Modeling
• Cardiomyocytes For Heart Disease Studies
• Endothelial Cells For Vascular Research

7. Induced Pluripotent Stem Cell (iPSC) Market Regional And Country Analysis

• 7.1. Global Induced Pluripotent Stem Cell (iPSC) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Induced Pluripotent Stem Cell (iPSC) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market

• 8.1. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Induced Pluripotent Stem Cell (iPSC) Market

• 9.1. China Induced Pluripotent Stem Cell (iPSC) Market Overview
• 9.2. China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Induced Pluripotent Stem Cell (iPSC) Market

• 10.1. India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Induced Pluripotent Stem Cell (iPSC) Market

• 11.1. Japan Induced Pluripotent Stem Cell (iPSC) Market Overview
• 11.2. Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Induced Pluripotent Stem Cell (iPSC) Market

• 12.1. Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Induced Pluripotent Stem Cell (iPSC) Market

• 13.1. Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Induced Pluripotent Stem Cell (iPSC) Market

• 14.1. South Korea Induced Pluripotent Stem Cell (iPSC) Market Overview
• 14.2. South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Induced Pluripotent Stem Cell (iPSC) Market

• 15.1. Western Europe Induced Pluripotent Stem Cell (iPSC) Market Overview
• 15.2. Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Induced Pluripotent Stem Cell (iPSC) Market

• 16.1. UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Induced Pluripotent Stem Cell (iPSC) Market

• 17.1. Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Induced Pluripotent Stem Cell (iPSC) Market

• 18.1. France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Induced Pluripotent Stem Cell (iPSC) Market

• 19.1. Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Induced Pluripotent Stem Cell (iPSC) Market

• 20.1. Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market

• 21.1. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market Overview
• 21.2. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Induced Pluripotent Stem Cell (iPSC) Market

• 22.1. Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Induced Pluripotent Stem Cell (iPSC) Market

• 23.1. North America Induced Pluripotent Stem Cell (iPSC) Market Overview
• 23.2. North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Induced Pluripotent Stem Cell (iPSC) Market

• 24.1. USA Induced Pluripotent Stem Cell (iPSC) Market Overview
• 24.2. USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Induced Pluripotent Stem Cell (iPSC) Market

• 25.1. Canada Induced Pluripotent Stem Cell (iPSC) Market Overview
• 25.2. Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Induced Pluripotent Stem Cell (iPSC) Market

• 26.1. South America Induced Pluripotent Stem Cell (iPSC) Market Overview
• 26.2. South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Induced Pluripotent Stem Cell (iPSC) Market

• 27.1. Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Induced Pluripotent Stem Cell (iPSC) Market

• 28.1. Middle East Induced Pluripotent Stem Cell (iPSC) Market Overview
• 28.2. Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Induced Pluripotent Stem Cell (iPSC) Market

• 29.1. Africa Induced Pluripotent Stem Cell (iPSC) Market Overview
• 29.2. Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Induced Pluripotent Stem Cell (iPSC) Market Competitive Landscape And Company Profiles

• 30.1. Induced Pluripotent Stem Cell (iPSC) Market Competitive Landscape
• 30.2. Induced Pluripotent Stem Cell (iPSC) Market Company Profiles
  • 30.2.1. FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific, Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Takara Bio, Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Astellas Pharma Inc Overview, Products and Services, Strategy and Financial Analysis

31. Induced Pluripotent Stem Cell (iPSC) Market Other Major And Innovative Companies

• 31.1. ViaCyte, Inc
• 31.2. Ncardia
• 31.3. REPROCELL USA, Inc
• 31.4. Japan Tissue Engineering Co., Ltd
• 31.5. Merck KGaA
• 31.6. Cynata Therapeutics Limited
• 31.7. Dainippon Sumitomo Pharma
• 31.8. Shenzhen Bioscience
• 31.9. Shanghai Cell Therapy Group
• 31.10. Car-T Bio
• 31.11. JW therapeutics
• 31.12. Fosun Kite Biotechnology
• 31.13. Shanghai UniCar Therapy
• 31.14. Takaria Bio
• 31.15. SEED Biosciences SA

32. Global Induced Pluripotent Stem Cell (iPSC) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Induced Pluripotent Stem Cell (iPSC) Market

34. Recent Developments In The Induced Pluripotent Stem Cell (iPSC) Market

35. Induced Pluripotent Stem Cell (iPSC) Market High Potential Countries, Segments and Strategies

• 35.1 Induced Pluripotent Stem Cell (iPSC) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Induced Pluripotent Stem Cell (iPSC) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Induced Pluripotent Stem Cell (iPSC) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer